HIV infection can be effectively treated by lifelong administration of combination antiretroviral
therapy, but an effective vaccine will likely be required to end the HIV epidemic. Although the …

Untreated HIV-1 infection typically progresses to AIDS within 10 years, but less than 1% of
infected individuals remain healthy and have normal CD4+ T cell counts and undetectable …

This report shows that a nanovector composed of peptide-based nanofibrous hydrogel can
condense DNA to result in strong immune responses against HIV. This nanovector can …

Human immunodeficiency virus type 1 (HIV-1) disease is pandemic, with approximately 36
million infected individuals world-wide. For the vast majority of these individuals, untreated …

The cellular immune response to HIV-1 has now been studied in extraordinary detail. A very
large body of data provides the most likely reasons that the HIV-specific cellular immune …

Elite controllers are HIV-1 positive subjects who control viral replication without antiretroviral
therapy. Many of these subjects have replication-competent virus and thus represent a …

An estimated 35 million people worldwide are infected with HIV, yet a widely applicable cure
strategy remains elusive. Recent case reports have suggested that curing HIV infection is …

The human immunodeficiency virus (HIV) infection of the immune cells expressing the
cluster of differentiation 4 cell surface glycoprotein (CD4+ cells) causes progressive decline …

Highly active antiretroviral therapy (HAART) suppresses HIV-1 replication, transforming the
outlook for infected patients. However, reservoirs of replication-competent forms of the virus …

HIV/AIDS is still a global threat despite the notable efforts made by the scientific and health
communities to understand viral infection, to design new drugs or to improve existing ones …